Progyny, Inc. (NASDAQ:PGNY) Receives $27.91 Consensus Price Target from Analysts

Progyny, Inc. (NASDAQ:PGNY) has earned a consensus recommendation of “Moderate Buy” from the thirteen analysts that are covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $27.9091.

PGNY has been the topic of several analyst reports. BTIG Research dropped their price target on shares of Progyny from $35.00 to $30.00 and set a “buy” rating on the stock in a research report on Thursday, March 5th. Citigroup raised shares of Progyny to an “outperform” rating in a research note on Tuesday, January 20th. Zacks Research cut Progyny from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Finally, Citizens Jmp raised Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 price target for the company in a report on Tuesday, January 20th.

Progyny Trading Down 0.7%

Shares of NASDAQ:PGNY opened at $16.86 on Monday. Progyny has a 12-month low of $16.59 and a 12-month high of $28.75. The business has a 50 day moving average of $20.11 and a two-hundred day moving average of $22.24. The company has a market capitalization of $1.38 billion, a PE ratio of 25.94, a PEG ratio of 0.98 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The business had revenue of $318.40 million for the quarter, compared to analysts’ expectations of $314.26 million. During the same quarter last year, the company earned $0.42 EPS. The business’s revenue was up 6.7% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Equities research analysts predict that Progyny will post 0.6 earnings per share for the current fiscal year.

Insider Activity at Progyny

In other news, EVP Allison Swartz sold 4,657 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total transaction of $81,031.80. Following the completion of the transaction, the executive vice president directly owned 89,879 shares of the company’s stock, valued at $1,563,894.60. This represents a 4.93% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders sold 7,455 shares of company stock valued at $129,515 in the last three months. 9.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Progyny

A number of institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada raised its position in Progyny by 384.8% during the first quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock worth $291,000 after acquiring an additional 10,340 shares during the period. Amundi grew its position in shares of Progyny by 103.8% in the first quarter. Amundi now owns 11,419 shares of the company’s stock valued at $264,000 after purchasing an additional 5,817 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Progyny by 6.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock valued at $5,630,000 after purchasing an additional 14,297 shares during the period. Cetera Investment Advisers increased its stake in shares of Progyny by 6.6% during the second quarter. Cetera Investment Advisers now owns 45,122 shares of the company’s stock worth $993,000 after purchasing an additional 2,809 shares in the last quarter. Finally, Legal & General Group Plc raised its position in shares of Progyny by 13.0% during the 2nd quarter. Legal & General Group Plc now owns 226,959 shares of the company’s stock worth $4,993,000 after purchasing an additional 26,153 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.